Evidence map›Paper›PMID 25573967›Full record

ArticleBlood2015

TET2 loss, a rescue of JAK2V617F HSCs.

William Vainchenker, Isabelle Plo

Open access · bronzeAbstract readComment
PubMed Publisher
In one paragraph

Article in Blood, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

William VainchenkerINSTITUT DE CANCÉROLOGIE GUSTAVE ROUSSY.
Isabelle PloINSTITUT DE CANCÉROLOGIE GUSTAVE ROUSSY.
Institut Gustave Roussy · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In this issue of Blood, Chen et al and Kameda et al demonstrate that Tet2 loss has 2 effects in Jak2V617F mice: it increases both the severity of the myeloproliferative disorders and the self-renewal properties of the Jak2V617F hematopoietic stem cells (HSCs).

Indexed as

AnimalsDioxygenasesDNA-Binding ProteinsHematopoietic Stem CellsJanus Kinase 2Myeloproliferative DisordersProto-Oncogene ProteinsDioxygenasesDNA-Binding ProteinsJak2 protein, mouseJanus Kinase 2Proto-Oncogene ProteinsTet2 protein, mouse

Identifiers

PMID25573967
OpenAlexW1970005179

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.